Washington University/Siteman Cancer Center Lead Academic Site

项目摘要 拟议中的华盛顿大学/Siteman癌症中心的基本目标是 (WU/SCC）NCTN领导学术参与站点UG 1将1）培养科学领导力， 在NCTN的指导，2）参与NCTN治疗，相关， 和癌症控制试验，以及3）在多种疾病的临床试验中保持强劲的增长 包括那些分子驱动的和那些罕见的癌症。WU/SCC 调查人员长期以来一直热情参与前合作组 计划，并继续在当前的NCTN计划中发挥关键作用，特别是联盟 肿瘤临床试验，ECOG-ACRIN癌症研究小组和NRG肿瘤学。 WU/SCC将由5名UG 1共同主要研究者组成高级领导团队 包括南希·L Bartlett，MD（肿瘤内科教授），Benjamin Kozower，MD，MPH （教授，胸部肿瘤学），大卫G. Mutch，MD（妇科肿瘤学教授）， Clifford罗宾逊，医学博士（放射肿瘤学副教授）和巴里A. Siegel，MD （放射学教授）。WU/SCC高级领导团队由三个传统成员组成， 具有广泛合作小组和NCTN经验的成员（Bartlett、Mutch和Siegel） 以及两名具有NCTN试验开发经验的新成员（罗宾逊和Kozower）。 整个领导团队致力于为整个机构的NCTN提供指导 UG1. WU/SCC一直表现出对NCTN试验的稳健应计，累计848 2014年3月至2017年8月期间的患者。在同一时期，535名患者 收集生物标本，58例患者进行高级成像研究。的 WU/SCC基因组学，蛋白质基因组学和分子成像计划的优势， 与大型机构生物储存库相结合，使我们能够进行重大而新颖的研究。 对NCTN的科学使命的贡献。WU/SCC调查人员仍然高度重视 投资于NCTN在AML、淋巴瘤、肺癌、乳腺癌、 癌症、肉瘤、子宫癌、分子成像和放射肿瘤学。另外我们 大转诊基地和新的癌症病例在我们的中心看到的大幅增加， 过去的5年将提高我们为几乎所有疾病部位方案招募患者的能力， 包括罕见的肿瘤这个全机构的UG 1将促进加强沟通， 疾病部位，翻译和模态专家之间的合作，并改善我们的 对NCTN业务的贡献潜力。

Project Summary The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) NCTN Lead Academic Participating Site UG1 is to 1) foster scientific leadership and mentorship in the NCTN, 2) participate in the development of NCTN therapeutic, correlative, and cancer control trials, and 3) maintain strong accrual to clinical trials across multiple disease sites, including those that are molecularly driven and those for rare cancers. WU/SCC investigators have a long history of enthusiastic participation in the former cooperative group program and continue to play key roles in the current NCTN program, specifically the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 UG1 co-Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Benjamin Kozower, MD, MPH (Professor, Thoracic Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology), Clifford Robinson, MD (Associate Professor, Radiation Oncology) and Barry A. Siegel, MD (Professor, Radiology). The WU/SCC senior leadership team is composed of three legacy members with extensive cooperative group and NCTN experience (Bartlett, Mutch and Siegel) and two new members (Robinson and Kozower) with experience in NCTN trial development. The entire leadership team is committed to providing guidance for an institution-wide NCTN UG1. WU/SCC has consistently demonstrated robust accrual to NCTN trials, accruing 848 patients between March 2014 and August 2017. During this same interval, 535 patients had biospecimens collected and 58 patients were accrued to advanced imaging studies. The strength of the WU/SCC genomics, proteogenomics, and molecular imaging programs in combination with the large institutional biorepositories position us to make significant and novel contributions to the scientific mission of the NCTN. WU/SCC investigators remain highly invested in NCTN translational and clinical research in AML, lymphoma, lung cancer, breast cancer, sarcoma, uterine cancer, molecular imaging, and radiation oncology. In addition, our large referral base and the substantial increase in new cancer cases seen at our center in the last 5 years will enhance our ability to accrue patients to nearly all disease site protocols, including rare tumors. This institution-wide UG1 will facilitate enhanced communication and collaboration among disease-site, translational, and modality specialists and improve our potential for contributions to the NCTN operation.